Featured Industry Insights
“I’ve Never Seen Anything as Effective”: Exploring the Combination of Psychedelics and Psychotherapy
While most psychedelic drugs remain illegal in the United States, ketamine has been legal for use by registered practitioners since the 1960s. With the recent recognition of the compound’s use as an antidepressant, more and more clinics are rolling out ketamine-assisted psychotherapy programs.
MEG Neuroimaging: The Magnetic Might Keeping Time on the Brain’s Hidden Secrets
Magnetoencephalography (MEG) is a neuroimaging technique that peers inside the brain by detecting incredibly weak magnetic signals produced by neurons. We spoke with Dimitrios Pantazis, who is director of the MEG lab at the Institute’s Martinos Imaging Center, to find out more about this powerful technology.
Latest Industry Insights
Keeping Pace With Trends and Developments in Analytical Science
Technology Networks spoke with Peter Zipfell to learn more about the Innovation Summits and the key themes that will be explored at the events. In this interview, Peter also shares his thoughts on current trends in analytical technologies and software.
Building the World’s First University Cloud Lab
To learn more about the CMU Cloud Lab, the motivation behind the project and the benefits it will bring, Technology Networks spoke to Rebecca Doerge, PhD, dean, Mellon College of Science, Carnegie Mellon University, and Toby Blackburn, head of business development and research, Emerald Cloud Lab.
Early Detection of Brain Tumors and Beyond
The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm3 from a blood sample in as little as fifteen minutes.
Gaining MOMENTUM in Optimizing the Clinical Use of Cutting-Edge, Personalized Cancer Treatments
This article explores how the expanded use of systematic, collaborative registries should allow the medical device, pharmaceutical and oncology communities to gain additional momentum on the road toward personalized cancer care.
Simplifying Complex Wound Care With Innovative Medical Technologies
Technology Networks recently spoke with Richard Hague, PolarityTE’s chief executive officer and president, to learn more about the science behind SkinTE and how it could overcome some of the limitations associated with other chronic wound treatments.
Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows
In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.
Brooks Automation To Unify Services Under Azenta Life Sciences
Technology Networks spoke to Linda De Jesus, senior vice president and chief commercial officer at Azenta Life Sciences to find out more about the announcement and how this will help drive innovation with greater speed and accuracy.
High-Quality Chemical Detection Where It Is Needed Most
To find out more about HPIMS, Technology Networks spoke with Dr. Ching Wu, founder and chief executive officer at Excellims and a pioneer of HPIMS. In this interview, Dr. Wu talks about the advantages that the technique can offer in applications ranging from pharma PAT to clinical diagnostics, and discusses how Excellims is increasing accessibility to the technology.
The Golden Age of Computer-Assisted Structure Elucidation (CASE)
Dimitris Argyropoulos explores the history of CASE and some of the ways it can be used to help scientists.
Genomic Testing Service To Drive Personalized Medicine for Cancer Patients
The service will enable oncologists, hematologists and other healthcare professionals to undertake rapid and extensive genomic analysis of cancer samples on an unprecedented scale in the UK.